417 related articles for article (PubMed ID: 35191283)
41. Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation.
Kannt A; Đikić I
Cell Chem Biol; 2021 Jul; 28(7):1014-1031. PubMed ID: 33945791
[TBL] [Abstract][Full Text] [Related]
42. E3-ligase knock down revealed differential titin degradation by autopagy and the ubiquitin proteasome system.
Müller E; Salcan S; Bongardt S; Barbosa DM; Krüger M; Kötter S
Sci Rep; 2021 Oct; 11(1):21134. PubMed ID: 34702928
[TBL] [Abstract][Full Text] [Related]
43. PROTACs: An Emerging Therapeutic Modality in Precision Medicine.
Nalawansha DA; Crews CM
Cell Chem Biol; 2020 Aug; 27(8):998-1014. PubMed ID: 32795419
[TBL] [Abstract][Full Text] [Related]
44. Cullin-RING E3 Ubiquitin Ligases: Bridges to Destruction.
Nguyen HC; Wang W; Xiong Y
Subcell Biochem; 2017; 83():323-347. PubMed ID: 28271482
[TBL] [Abstract][Full Text] [Related]
45. The Potential of Proteolytic Chimeras as Pharmacological Tools and Therapeutic Agents.
Coll-Martínez B; Delgado A; Crosas B
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339292
[TBL] [Abstract][Full Text] [Related]
46. Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues.
Ramachandran S; Ciulli A
Curr Opin Struct Biol; 2021 Apr; 67():110-119. PubMed ID: 33271439
[TBL] [Abstract][Full Text] [Related]
47. Discovery of a Covalent FEM1B Recruiter for Targeted Protein Degradation Applications.
Henning NJ; Manford AG; Spradlin JN; Brittain SM; Zhang E; McKenna JM; Tallarico JA; Schirle M; Rape M; Nomura DK
J Am Chem Soc; 2022 Jan; 144(2):701-708. PubMed ID: 34994556
[TBL] [Abstract][Full Text] [Related]
48. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
49. Exploring the Rampant Expansion of Ubiquitin Proteomics.
Rose A; Mayor T
Methods Mol Biol; 2018; 1844():345-362. PubMed ID: 30242720
[TBL] [Abstract][Full Text] [Related]
50. Dynamics of Ubiquitination in Differentiation and Dedifferentiation of Pancreatic β-cells: Putative Target for Diabetes.
Francis M; Bhaskar S; Vishnuvajhala S; Prasanna J; Kumar A
Curr Protein Pept Sci; 2022; 23(9):602-618. PubMed ID: 35466872
[TBL] [Abstract][Full Text] [Related]
51. A synthetic KLHL20 ligand to validate CUL3
Farrell BM; Gerth F; Yang CR; Yeh JT
Genes Dev; 2022 Sep; 36(17-18):1031-1042. PubMed ID: 36328355
[TBL] [Abstract][Full Text] [Related]
52. Ubiquitin-Proteasome Pathway and Muscle Atrophy.
Khalil R
Adv Exp Med Biol; 2018; 1088():235-248. PubMed ID: 30390254
[TBL] [Abstract][Full Text] [Related]
53. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
54. Investigation of the molecular mechanism of δ-catenin ubiquitination: Implication of β-TrCP-1 as a potential E3 ligase.
Shrestha H; Yuan T; He Y; Moon PG; Shrestha N; Ryu T; Park SY; Cho YC; Lee CH; Baek MC; Cho S; Simkhada S; Kim H; Kim K
Biochim Biophys Acta; 2016 Sep; 1863(9):2311-21. PubMed ID: 27316454
[TBL] [Abstract][Full Text] [Related]
55. PROTAC-induced proteolytic targeting.
Carmony KC; Kim KB
Methods Mol Biol; 2012; 832():627-38. PubMed ID: 22350917
[TBL] [Abstract][Full Text] [Related]
56. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Mahan SD; Riching KM; Urh M; Daniels DL
Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
[TBL] [Abstract][Full Text] [Related]
57. Testing the Effects of SIAH Ubiquitin E3 Ligases on Lysine Acetyl Transferases.
Hagenbucher J; Stekman H; Rodriguez-Gil A; Kracht M; Schmitz ML
Methods Mol Biol; 2017; 1510():297-312. PubMed ID: 27761830
[TBL] [Abstract][Full Text] [Related]
58. The Present and Future of Novel Protein Degradation Technology.
Xia L; Liu W; Song Y; Zhu H; Duan Y
Curr Top Med Chem; 2019; 19(20):1784-1788. PubMed ID: 31644408
[TBL] [Abstract][Full Text] [Related]
59. Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy.
Verma R
Adv Exp Med Biol; 2021; 1322():339-357. PubMed ID: 34258747
[TBL] [Abstract][Full Text] [Related]
60. Mechanistic and Structural Features of PROTAC Ternary Complexes.
Casement R; Bond A; Craigon C; Ciulli A
Methods Mol Biol; 2021; 2365():79-113. PubMed ID: 34432240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
